Tonghua Golden-Horse Pharmaceutical Industey Co.Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Tonghua Jinma Pharmaceutical Group Co., Ltd. was established in 1990 and underwent a joint-stock reform. In 1997, the company's stock was listed on the Shenzhen Stock Exchange (stock code 000766). It is one of the earliest pharmaceutical enterprises to be listed in the country, with first-class domestic standard factories, GMP production lines, and quality management systems. It is a comprehensive pharmaceutical enterprise that integrates drug production, sales, and research and development. In the initial stage of the group's development, diversified and multi line development is adopted, with product lines covering multiple diseases and departments, gradually focusing on core areas. In the future, Tonghua Jinma will focus on the big health industry as the main line, with medicine and medical treatment as the core, covering multiple sectors such as medicine, medical treatment, investment, consumption, etc., to create a full industry chain of big health. Faced with the international and domestic trends in medicine, Tonghua Jinma has adapted to the situation and made a comprehensive transformation, adopting a "dual wheel drive" development strategy of endogenous development and external expansion. Through the endogenous development of "quality based and brand oriented" and the extension expansion of "enterprise mergers and acquisitions, restructuring, and integration", we aim to reshape the brand, market accordingly, expand capital, and promote the sustainable development of the enterprise. Comprehensively create a "new golden horse, new image", strive to achieve the company's "new development, new leap", and become a highly dynamic and competitive comprehensive pharmaceutical and medical listed group company. The acquisition of Beijing Jinshang Alliance Holdings Co., Ltd. in 2013 injected vitality into Tonghua Jinma. On August 12, 2015, Tonghua Jinma invested 2.68 billion yuan to acquire 100% equity of Shengtai Biotechnology, which added wings to the development of the enterprise. After the acquisition, Tonghua Jinma covered multiple product lines such as traditional Chinese medicine, Chinese and Western raw materials, and biochemical preparations. Especially, Shengtai Biopharmaceutical has formed a variety advantage centered on multiple types of drugs such as skeletal muscle, cardiovascular and cerebrovascular diseases, and respiratory systems, which has a good synergy and complementary effect with Tonghua Jinma's main business. In January 2016, Tonghua Jinma increased its capital to Changchun Huayang and acquired 60% of its equity; Acquire 30% equity of Jiangsu Shen'eryang Technology Co., Ltd. In May 2016, two investment companies and three fund companies were established, with a medical M&A fund scale of 5 billion yuan. In July 2016, a total of 414 million yuan was invested to successfully acquire 100% equity of Chengdu Yongkang Pharmaceutical. And relying on the forest musk deer breeding base owned by Yongkang Pharmaceutical, we will continue to promote the development strategy of high-quality Chinese medicine by controlling the supply and quality of key raw materials, and establish a leading position in the segmented drug market. In August 2016, it invested 1.785 billion yuan to acquire 85% equity of over 40 hospitals of Heilongjiang Longmei Group, including 5 tertiary hospitals. In March 2018, invested 19 million yuan to acquire 100% equity of Jiangxi Fengma; In May 2018, invested 110 million yuan to acquire 100% equity of Yuanshou Pharmaceutical; In June 2018, it invested 45 million yuan to acquire 22% equity of Beijing Minkang Baicao Pharmaceutical Technology, 30 million yuan to acquire 21% equity of Shanghai Shijian Biotechnology Co., Ltd. In March 2019, it invested 50 million yuan to acquire 80% equity of Peking University Shijia Research Institute. At this point, Tonghua Jinma Pharmaceutical Group has established complete research and development capabilities in the fields of traditional Chinese medicine, chemical medicine, and biopharmaceuticals, further enhancing its research and development capabilities. In some areas, its research and development capabilities are at the world's leading level, providing the strongest guarantee for the group's product layout. After the completion of the restructuring of Tonghua Jinma in 2016, the most important task is to sort out the products and reshape the Jinma brand. All products with quality defects will be discontinued. Before the restructuring, Tonghua Jinma had 109 product batches and 79 products in production and on sale, resulting in multiple production and management failures. After the restructuring, the overall focus is on product quality, combined with the structural reform of the drug supply side, and from the aspects of production capacity, quality, finance, and market demand, we will carry out a large-scale rectification and sorting of products. Any products that consumers are dissatisfied with or even have slight quality defects will be discontinued or recalled. After strict rectification and sorting, currently only 32 products are retained for production, including 12 exclusive varieties and 5 medical insurance varieties. Tonghua Jinma has always regarded product research and development capabilities as an important guarantee for product quality and market potential exploration. Over the years, it has established technical cooperation relationships with more than 20 universities and research units, including Changchun College of Traditional Chinese Medicine, Tianjin Institute of Pharmacy, and Peking University School of Life Sciences. At the same time, it allocates 3% of its annual revenue for product research and development, increases support for the industrialization of research and development of new drug achievements, and preliminarily constructs the company's product framework. In 2016, while subtracting products, Tonghua Jinma used capital as a tool for addition, quickly upgrading its product structure and expanding its market layout.At the same time as initiating the consistency evaluation of generic drugs, efforts will be made to increase the research and development of new drugs and generic drugs. Phase III clinical trials of Class 1.1 chemical drugs for treating Alzheimer's disease are progressing smoothly, and the GMP factory renovation and construction of raw material drug factories will be completed in 2019. It is expected to be declared in 2020 and launched in 2021. The launch of this major new drug will greatly fill the unmet clinical demand and fill the gap in China's treatment of Alzheimer's disease drugs, which is also a leading global drug. At the same time, more than 20 competitive generic drug new products that have undergone strict market evaluation and screening by the group will also be developed and launched in the next three years, laying a solid foundation for the stable and sustainable development of the group. In 2019, Tonghua Jinma Group seized the opportunity to enter the industrial hemp industry. In Jilin and Heilongjiang provinces, it signed tripartite cooperation agreements with the most powerful research and development institutions, Jilin Academy of Agricultural Sciences, Heilongjiang Academy of Sciences and its branches, and corresponding municipal governments. It also registered two Hanma Technology companies to quickly land and connect, layout the entire CBD industry chain, and provide momentum for the group's deep development in the field of big health, Assist in achieving the strategic goal of diversified development of big health. Since the Jin Merchants Alliance took over, the market value of Tonghua Jinma has increased from 2 billion yuan to 23 billion yuan at its highest level, with a growth rate of 1050% in three years. It ranks 26th among 165 pharmaceutical listed companies in China in terms of market value. In the past three years, enterprises have achieved significant growth in assets, market size, and tax payment. In 2016, the company's total assets were 5.3 billion yuan, with a growth rate of 27.6%; The market size is 3.82 billion yuan, with a growth rate of 377%; The tax paid was 143 million yuan, with a growth rate of 533%. Meanwhile, due to the restructuring and listing of the company, shareholders paid a transaction tax of 140 million yuan to the location of the company in 2016, contributing to local financial and tax revenue and economic development. In 2017, the company's total assets were 5.7 billion yuan, with a growth rate of 7.5%; The market size is 4.56 billion yuan, with a growth rate of 19.3%; The tax paid was 256 million yuan, with a growth rate of 79.1%. In 2018, the total assets were 6 billion yuan, the market size was 4.19 billion yuan, and the tax paid was 254 million yuan. In the process of comprehensively strengthening the control and operation of the group, Tonghua Jinma Pharmaceutical Group is enthusiastic about social public welfare undertakings and actively returns to society. It has made great efforts to do a good job in assisting the poor and the weak, and donating to the Hope Project. It actively practices national environmental protection requirements, firmly establishes the environmental concept of "green waters and green mountains are gold and silver mountains", comprehensively upgrades sewage treatment equipment, renovates boiler facilities, and ensures that the company's sewage and exhaust emissions fully comply with national standards, in order to achieve national health Contribute to the Golden Horse wisdom, Golden Horse plan, and Golden Horse strength in achieving a comprehensive well-off society and winning the Blue Sky and River Defense War. In 2017, we donated over 560000 yuan in medicine to Zhijin County, a poverty-stricken county in Guizhou. Tonghua Jinma has been repeatedly rated as one of China's top 100 traditional Chinese medicine pharmaceutical enterprises, one of China's top 100 pharmaceutical industry enterprises, and one of China's top 50 pharmaceutical industry growth enterprises. The product has been awarded the title of "Famous Brand" multiple times by the Development Research Center of Jilin Provincial People's Government, Jilin Provincial Quality Management Association, and Jilin Provincial Drug Quality Supervision and Administration. The company has been awarded the title of Advanced Collective in the National Medical System by the National Drug Administration, named as a Provincial High tech Enterprise by the provincial government, and named a well-known pharmaceutical enterprise in the pharmaceutical industry by the Provincial Science and Technology Commission and the Provincial Drug Administration. In 2017, Tonghua Jinma successfully passed the National Enterprise Credit Rating Certification of the Credit Work Office of the Ministry of Commerce, and was awarded the National Enterprise AAA Credit Rating Certificate. In the Second Drug Regulatory Conference, the Integrity Declaration of 100 Enterprises: To Be a Law-abiding Role Model and Create a Honest Enterprise, Tonghua Jinma was named a Law-abiding and Honest Enterprise for two consecutive years from 2017 to 2018. In 2018, Tonghua Jinma was selected for the 2017 Golden Bull Most Valuable Investment Award. Mr. Ji Yanfeng, General Manager, was honored as one of the top ten leading figures in the Chinese pharmaceutical industry in 2016, and was honored as one of the top ten new leading figures in the Chinese pharmaceutical industry in 2018 in 2019. |
| Headquarter | Tonghua |
| Establish Date | 2/26/1993 |
| Listed Code | 000766.SZ |
| Listed Date | 4/30/1997 |
| Chairman | Zhang Yufu. |
| CEO | Zhang Haoyan. |
| Website | www.thjm.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
